{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"limitationsAndCaveats":{"description":"Due to a substantial decline in the use of the VAD regimen as standard of care, recruitment of the study was halted at 30 subjects. It was not possible to statistically evaluate any long term efficacy parameter."},"pointOfContact":{"email":"rangermu@its.jnj.com","organization":"Jan-Cilag Germany","phone":"+49 2137 955-492","title":"EMEA Medical Affairs Director Oncology"}}